79 related articles for article (PubMed ID: 28387912)
1. DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.
Liu J; Li T; Liu XL
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1206-1213. PubMed ID: 28387912
[TBL] [Abstract][Full Text] [Related]
2. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.
Xie L; Li T; Yang LH
Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2150-2156. PubMed ID: 28537669
[TBL] [Abstract][Full Text] [Related]
3. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
4. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
Ocaña A; Pérez-Peña J; Alcaraz-Sanabria A; Sánchez-Corrales V; Nieto-Jiménez C; Templeton AJ; Seruga B; Pandiella A; Amir E
Oncotarget; 2016 Apr; 7(16):22865-72. PubMed ID: 26992217
[TBL] [Abstract][Full Text] [Related]
5. NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.
Niu C; Sun X; Zhang W; Li H; Xu L; Li J; Xu B; Zhang Y
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775588
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis.
Yang X; Zhang L; Xie L
Med Sci Monit; 2018 Jun; 24():3863-3872. PubMed ID: 29880787
[TBL] [Abstract][Full Text] [Related]
7. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
[TBL] [Abstract][Full Text] [Related]
8. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
Steller MD; Shaw TJ; Vanderhyden BC; Ethier JF
Mol Cancer Res; 2005 Jan; 3(1):50-61. PubMed ID: 15671249
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of S100 family members in ovarian cancer patients.
Bai Y; Li LD; Li J; Lu X
BMC Cancer; 2018 Dec; 18(1):1256. PubMed ID: 30558666
[TBL] [Abstract][Full Text] [Related]
10. High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells.
Volkmann J; Reuning U; Rudelius M; Häfner N; Schuster T; Becker V Ros A; Weimer J; Hilpert F; Kiechle M; Dürst M; Arnold N; Schmalfeldt B; Meindl A; Ramser J
Int J Cancer; 2013 Jun; 132(12):2820-32. PubMed ID: 23225306
[TBL] [Abstract][Full Text] [Related]
11. CDH17 is a downstream effector of HOXA13 in modulating the Wnt/β-catenin signaling pathway in gastric cancer.
Qu LP; Zhong YM; Zheng Z; Zhao RX
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1234-1241. PubMed ID: 28387908
[TBL] [Abstract][Full Text] [Related]
12. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
13. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
14. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
[TBL] [Abstract][Full Text] [Related]
16. The expression and biological effect of NR2F6 in non-small cell lung cancer.
Yang SL; Guan HQ; Yang HB; Chen Y; Huang XY; Chen L; Shen ZF; Wang LX
Front Oncol; 2022; 12():940234. PubMed ID: 36119482
[TBL] [Abstract][Full Text] [Related]
17. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
18. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
[TBL] [Abstract][Full Text] [Related]
20. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
